Thermo Fisher Scientific to Acquire Clario Holdings for $8.875 Billion

Thermo Fisher Scientific Acquires Olink Holding AB

July 10, 2024

Biotechnology

Thermo Fisher Scientific completed the acquisition of Olink Holding AB (publ) via a public cash tender offer at USD 26.00 per share/ADS, buying the proteomics company from shareholders including Summa Equity. The acquisition strengthens Thermo Fisher’s proteomics and protein-analysis capabilities, adding Olink’s high‑multiplex protein detection technology to its life‑science tools portfolio.

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed its acquisition of PPD, Inc., a leading global provider of clinical research services, for $17.4 billion. The deal extends Thermo Fisher’s clinical research capabilities across the drug development spectrum and is expected to generate total synergies of approximately $125 million by year three following close.

Clario Acquires NeuroRx

March 19, 2025

Healthcare Services

Clario has acquired NeuroRx, a Montreal-based imaging analysis provider specializing in neuroimaging for clinical trials, to strengthen Clario's neuroscience capabilities. NeuroRx founder Douglas Arnold will join Clario as Senior Scientific Advisor as the company integrates NeuroRx's imaging expertise to support drug development in CNS indications.

WilsonHCG Acquires Claro Analytics

March 16, 2022

Data & Analytics

WilsonHCG, a global talent solutions firm based in Tampa, Florida, has acquired talent intelligence platform Claro Analytics to expand its real-time labor market and talent intelligence capabilities. The acquisition integrates Claro Analytics’ SaaS-based labor market data and analytics into WilsonHCG’s services to deliver on-demand and outsourced talent intelligence to enterprise clients.

Clario Acquires WCG's eCOA Business

May 6, 2025

Healthcare Services

Clario has acquired the electronic clinical outcome assessment (eCOA) business of WCG to expand its endpoint data solutions and deepen neuroscience-focused clinical outcomes expertise. The deal—announced in March and completed in May 2025—transfers WCG’s eCOA team and capabilities to Clario and is expected to enhance Clario’s support for complex neuroscience clinical trials.

Thermo Fisher Scientific Acquires The Binding Site Group

October 31, 2022

Medical Devices

Thermo Fisher Scientific has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital for £2.25 billion (about $2.6 billion). The Binding Site, a Birmingham-based specialist in protein and blood-cancer diagnostics with more than 1,100 employees and ~10% annual revenue growth, will join Thermo Fisher's Specialty Diagnostics segment to expand its capabilities in cancer diagnostics and monitoring.